Fluxion Biosciences has signed a distribution agreement for EMD Millipore’s PrecisION range of ion channel cell lines. The non-exclusive distribution agreement will combine Fluxion’s IonFlux automated patch clamp instrumentation with EMD Millipore’s suite of ion channel cell lines. Through the agreement, Fluxion will provide IonFlux customers with cell lines that have been performance validated on the IonFlux automated patch clamp platform, eliminating the risk and delays associated with the assay optimization process.
The IonFlux system tests ion channels by automating the traditional “patch clamp” technique, which allows the promising yet challenging ion channel drug target class to be screened in a physiologically relevant context. Ideal for a range of ion channel screening applications requiring 10 to 10,000 or more assays per day, the IonFlux automated patch clamp system combines flexibility and simplicity with time and cost savings. The recent introduction of the single cell giga-seal consumable completes the system capabilities that include high success rate cell ensemble recording and continuous perfusion. The IonFlux system provides an extremely compact plate reader format. A broad range of global biopharmaceutical companies and leading academic institutions has adopted the IonFlux system, including Pfizer, Novartis, Genentech, Sanofi-Aventis, Cornell, University of Melbourne, University of Michigan, and University of Wisconsin.
The availability of PrecisION cell lines through Fluxion is effective immediately. A broad range of IonFlux-validated cell lines is available, including hERG, GABA, and sodium channels.
Date: December 6, 2011
Source: Fluxion Biosciences
